HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) CME Activity Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kostakoglu, L. Articles by Goldsmith, S. J. Search for Related Content PubMed PubMed Citation Articles by Kostakoglu, L. Articles by Goldsmith, S. J.

¹⁸F-FDG PET Evaluation of the Response to Therapy for Lymphoma and for Breast, Lung, and Colorectal Carcinoma^*

Division of Nuclear Medicine, Department of Radiology, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, New York

PET is a unique form of diagnostic imaging that observes in vivo biologic changes using radiopharmaceuticals that closely mimic endogenous molecules. ¹⁸F-FDG, which allows the evaluation of glucose metabolism, is the most commonly used tracer in oncology because of the practical half-life of ¹⁸F (110 min), compared with other short-lived positron emitters. ¹⁸F-FDG uptake in tumors is proportional to the glycolytic metabolic rate of viable tumor cells indicating the increased metabolic demand of tumors for glucose. ¹⁸F-FDG PET significantly improves the accuracy of imaging tumors in initial staging, management of recurrent cancer, and monitoring of therapy response. The information provided by this technique is more sensitive and specific than that provided by anatomic imaging modalities. ¹⁸F-FDG PET is particularly superior to CT or MRI in the ability to evaluate the effectiveness of various treatment regimens early during therapy or after therapy. In this review, we discuss the role of ¹⁸F-FDG PET in evaluating the response to therapy and the impact of this information on patient management.

Key Words: ¹⁸F-FDG PET • therapy response • lymphoma • lung cancer • colorectal cancer • breast cancer

This article has been cited by other articles:

				M. Tatsumi, J. H. Miller, and R. L. Wahl 18F-FDG PET/CT in Evaluating Non-CNS Pediatric Malignancies J. Nucl. Med., December 1, 2007; 48(12): 1923 - 1931. [Abstract] [Full Text] [PDF]

				D. J. A. Margolis, J. M. Hoffman, R. J. Herfkens, R. B. Jeffrey, A. Quon, and S. S. Gambhir Molecular Imaging Techniques in Body Imaging Radiology, November 1, 2007; 245(2): 333 - 356. [Abstract] [Full Text] [PDF]

				C. Lin, E. Itti, C. Haioun, Y. Petegnief, A. Luciani, J. Dupuis, G. Paone, J.-N. Talbot, A. Rahmouni, and M. Meignan Early 18F-FDG PET for Prediction of Prognosis in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment Versus Visual Analysis J. Nucl. Med., October 1, 2007; 48(10): 1626 - 1632. [Abstract] [Full Text] [PDF]

				T. Okuma, T. Matsuoka, T. Okamura, Y. Wada, A. Yamamoto, Y. Oyama, K. Koyama, K. Nakamura, Y. Watanabe, and Y. Inoue 18F-FDG Small-Animal PET for Monitoring the Therapeutic Effect of CT-Guided Radiofrequency Ablation on Implanted VX2 Lung Tumors in Rabbits J. Nucl. Med., August 1, 2006; 47(8): 1351 - 1358. [Abstract] [Full Text] [PDF]

				H. A. Jacene, T. Ishimori, J. M. Engles, S. Leboulleux, V. Stearns, and R. L. Wahl Effects of Pegfilgrastim on Normal Biodistribution of 18F-FDG: Preclinical and Clinical Studies J. Nucl. Med., June 1, 2006; 47(6): 950 - 956. [Abstract] [Full Text] [PDF]

				O. Mawlawi, J. J. Erasmus, T. Pan, D. D. Cody, R. Campbell, A. H. Lonn, S. Kohlmyer, H. A. Macapinlac, and D. A. Podoloff Truncation Artifact on PET/CT: Impact on Measurements of Activity Concentration and Assessment of a Correction Algorithm. Am. J. Roentgenol., May 1, 2006; 186(5): 1458 - 1467. [Abstract] [Full Text] [PDF]

				M. Westerterp, H. L. van Westreenen, J. B. Reitsma, O. S. Hoekstra, J. Stoker, P. Fockens, P. L. Jager, B. L. F. Van Eck-Smit, J. T. M. Plukker, J. J. B. van Lanschot, et al. Esophageal Cancer: CT, Endoscopic US, and FDG PET for Assessment of Response to Neoadjuvant Therapy--Systematic Review Radiology, September 1, 2005; 236(3): 841 - 851. [Abstract] [Full Text] [PDF]

				W. A. Weber Use of PET for Monitoring Cancer Therapy and for Predicting Outcome J. Nucl. Med., June 1, 2005; 46(6): 983 - 995. [Abstract] [Full Text] [PDF]

				R. Sasaki, R. Komaki, H. Macapinlac, J. Erasmus, P. Allen, K. Forster, J. B. Putnam, R. S. Herbst, C. A. Moran, D. A. Podoloff, et al. [18F]Fluorodeoxyglucose Uptake by Positron Emission Tomography Predicts Outcome of Non-Small-Cell Lung Cancer J. Clin. Oncol., February 20, 2005; 23(6): 1136 - 1143. [Abstract] [Full Text] [PDF]

				P. W. Grigsby, B. A. Siegel, F. Dehdashti, J. Rader, and I. Zoberi Posttherapy [18F] Fluorodeoxyglucose Positron Emission Tomography in Carcinoma of the Cervix: Response and Outcome J. Clin. Oncol., June 1, 2004; 22(11): 2167 - 2171. [Abstract] [Full Text] [PDF]

				N. S. Majhail, J.-L. Urbain, J. M. Albani, M. H. Kanvinde, T. W. Rice, A. C. Novick, T. M. Mekhail, T. E. Olencki, P. Elson, and R. M. Bukowski F-18 Fluorodeoxyglucose Positron Emission Tomography in the Evaluation of Distant Metastases From Renal Cell Carcinoma J. Clin. Oncol., November 1, 2003; 21(21): 3995 - 4000. [Abstract] [Full Text] [PDF]